

# David A Braun

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9356737/publications.pdf>

Version: 2024-02-01

44  
papers

3,025  
citations

236833

25  
h-index

330025

37  
g-index

46  
all docs

46  
docs citations

46  
times ranked

3623  
citing authors

#	ARTICLE	IF	CITATIONS
1	HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. <i>Lancet Oncology</i> , The, 2022, 23, 172-184.	5.1	58
2	Integrative clinical and molecular characterization of translocation renal cell carcinoma. <i>Cell Reports</i> , 2022, 38, 110190.	2.9	40
3	Tumor-Infiltrating T Cells â€” A Portrait. <i>New England Journal of Medicine</i> , 2022, 386, 992-994.	13.9	10
4	Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial. <i>Clinical Cancer Research</i> , 2022, 28, 748-755.	3.2	9
5	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. <i>Clinical Cancer Research</i> , 2022, 28, 831-839.	3.2	12
6	Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). <i>Journal of Clinical Oncology</i> , 2022, 40, 2913-2923.	0.8	40
7	Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. <i>Nature</i> , 2022, 605, 532-538.	13.7	70
8	Molecular characterization of the tumor microenvironment in chromophobe renal cell carcinoma (ChRCC) and related oncocytic neoplasms.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4549-4549.	0.8	0
9	Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC): The JAVELIN Renal 101 experience.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4531-4531.	0.8	3
10	Dual <i>&gt;</i> CDKN2A/MTAP <i>&lt;/i&gt;loss compared to <i>&lt;i&gt;</i>CDKN2A<i>&lt;/i&gt; loss alone and response to immune-checkpoint inhibitors (ICI) in advanced solid tumors.. <i>Journal of Clinical Oncology</i>, 2022, 40, 2622-2622.</i></i>	0.8	0
11	Single cell transcriptomic characterization of natural killer (NK) cell populations in clear cell renal cell carcinoma and association with clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16521-e16521.	0.8	0
12	Fumarate hydratase-deficient renal cell carcinoma: The real-world experience at Dana-Farber Cancer Institute and Moores Cancer Center.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16522-e16522.	0.8	0
13	Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world experience.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6520-6520.	0.8	1
14	Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 4045-4055.	3.2	12
15	Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 244-256.	12.5	138
16	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1371-1380.	3.2	49
17	Optimized Liquid and Gas Phase Fractionation Increases HLA-Peptidome Coverage for Primary Cell and Tissue Samples. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100133.	2.5	32
18	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. <i>Nature Communications</i> , 2021, 12, 808.	5.8	84

#	ARTICLE	IF	CITATIONS
19	Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 649-661.e5.	7.7	263
20	Effect of high-dose corticosteroid use on efficacy of immune checkpoint inhibitors in patients with renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4583-4583.	0.8	0
21	Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 632-648.e8.	7.7	230
22	Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1454-1461.	1.9	6
23	<i>CDKN2A</i> Alterations and Response to Immunotherapy in Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 4025-4035.	3.2	51
24	Neurotoxicities of novel non-steroidal anti-androgens for prostate cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 166, 103463.	2.0	3
25	Beyond conventional immune-checkpoint inhibition – novel immunotherapies for renal cell carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 199-214.	12.5	179
26	Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2021, 7, 1815.	3.4	40
27	State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era. <i>European Urology Focus</i> , 2020, 6, 37-40.	1.6	6
28	Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2020, 3, 372-381.	2.6	59
29	Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. <i>Journal of Clinical Oncology</i> , 2020, 38, 63-70.	0.8	109
30	A large peptidome dataset improves HLA class I epitope prediction across most of the human population. <i>Nature Biotechnology</i> , 2020, 38, 199-209.	9.4	324
31	Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). <i>Journal of Clinical Oncology</i> , 2020, 38, 4240-4248.	0.8	69
32	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. <i>Nature Medicine</i> , 2020, 26, 909-918.	15.2	488
33	Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. <i>European Journal of Cancer</i> , 2020, 135, 203-210.	1.3	50
34	Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma. <i>Genetics in Medicine</i> , 2020, 22, 1366-1373.	1.1	40
35	Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. <i>Cancer Immunology Research</i> , 2020, 8, 1075-1084.	1.6	47
36	OTHR-04. INCIDENCE AND SURVIVAL OUTCOMES IN UROTHELIAL CARCINOMA BRAIN METASTASES. <i>Neuro-Oncology Advances</i> , 2019, 1, i18-i19.	0.4	0

#	ARTICLE	IF	CITATIONS
37	PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. <i>Clinical Cancer Research</i> , 2019, 25, 6080-6088.	3.2	50
38	What was old is new again: learning from the modern master clinician. <i>Clinical Teacher</i> , 2019, 16, 274-276.	0.4	0
39	Clinical Validation of <i>PBRM1</i> Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2019, 5, 1631.	3.4	166
40	Metabolomic adaptations and correlates of survival to immune checkpoint blockade. <i>Nature Communications</i> , 2019, 10, 4346.	5.8	139
41	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 2174-2184.	3.2	80
42	A Disturbing Decline. <i>New England Journal of Medicine</i> , 2019, 380, 2257-2262.	13.9	2
43	Acquired mechanisms of immune escape in cancer following immunotherapy. <i>Genome Medicine</i> , 2018, 10, 87.	3.6	51
44	Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. <i>Cancer Journal (Sudbury,)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.8	8